8-K: RxSight Reports Strong First Quarter 2025 Results, Driven by Light Adjustable Lens Sales

RxSight's first quarter 2025 revenue increased by 28% year-over-year to $37.9 million, fueled by strong sales of Light Adjustable Lenses and Light Delivery Devices.

Summary

• RxSight, Inc. reported its financial results for the first quarter of 2025.
• Total revenue reached $37.9 million, a 28% increase compared to the first quarter of 2024.
• This growth was primarily driven by a 37% increase in Light Adjustable Lens (LAL) revenue and an 8% increase in Light Delivery Device (LDD) revenue.
• The company sold 27,579 LALs, representing a 36% increase in procedure volume.
• RxSight sold 73 LDDs, bringing the total installed base to 1,044 as of March 31, 2025, a 43% increase year-over-year.
• Gross profit for the quarter was $28.3 million, or 74.8% of revenue, compared to $20.7 million, or 70.1% of revenue, in the first quarter of 2024.
• Operating expenses increased by 24% to $39.0 million, reflecting investments in growing the LDD installed base, supporting LAL sales, and advancing R&D.
• The company reported a net loss of $(8.2) million, or $(0.20) per share, compared to a net loss of $(9.1) million, or $(0.25) per share, in the first quarter of 2024.
• Adjusted net loss was $(1.1) million, or $(0.03) per share, compared to $(4.4) million, or $(0.12) per share, in the first quarter of 2024.
• Cash, cash equivalents, and short-term investments decreased by $7.9 million to $229.3 million as of March 31, 2025.
• RxSight reiterated its full-year 2025 revenue guidance of $160.0 million to $175.0 million, gross margin guidance of 71% to 73%, and operating expense guidance of $150.0 million to $160.0 million.

Sentiment

Score: 7

Explanation: The report is generally positive due to strong revenue growth, improved gross margins, and reiterated guidance. However, the net loss and increased operating expenses temper the overall sentiment.

Positives

• Significant revenue growth driven by strong LAL and LDD sales.
• Improved gross profit margin due to lower cost of sales and favorable product mix.
• Increased installed base of LDDs, indicating growing market adoption.
• Reiteration of full-year 2025 guidance, demonstrating confidence in future performance.
• Reduced adjusted net loss compared to the same period last year.

Negatives

• The company reported a net loss of $(8.2) million for the quarter.
• Operating expenses increased by 24%, impacting profitability.
• Cash, cash equivalents, and short-term investments decreased by $7.9 million during the quarter.

Risks

• The company's forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially.
• Increased operating expenses could impact future profitability.
• The company's success depends on continued adoption of its Light Adjustable Lens technology.

Future Outlook

The company reiterated its 2025 full-year revenue guidance of $160.0 million to $175.0 million, gross margin guidance of 71% to 73%, and operating expense guidance of $150.0 million to $160.0 million.

Management Comments

• Ron Kurtz, Chief Executive Officer and President of RxSight, stated that the exceptional clinical value of the Light Adjustable Lens continues to drive significant enthusiasm among cataract surgeons.
• Management believes that customization and post-operative adjustability are shaping the future of premium cataract surgery.
• The company believes it is well-positioned to lead the next chapter of growth in the premium IOL market due to strong customer and patient interest, an innovative product pipeline, the expansion of third-party light treatment service center business models, and recent international regulatory approvals.

Industry Context

RxSight operates in the ophthalmic medical device industry, specifically focusing on cataract surgery and intraocular lenses (IOLs). The company's Light Adjustable Lens system offers a unique post-operative adjustability feature, differentiating it from traditional IOLs and positioning it within the premium segment of the market.

Comparison to Industry Standards

• Alcon, Johnson & Johnson Vision, and Bausch + Lomb are major players in the IOL market.
• RxSight's focus on post-operative adjustability with the LAL sets it apart from competitors offering primarily fixed-power IOLs.
• The 28% revenue growth in Q1 2025 indicates strong market traction compared to the overall growth rate of the premium IOL market.
• The gross margin of 74.8% is competitive within the medical device industry.

Stakeholder Impact

• Shareholders will likely react positively to the revenue growth and improved gross margins.
• Employees may benefit from the company's growth and investments in R&D.
• Customers (cataract surgeons) are showing enthusiasm for the Light Adjustable Lens.
• Patients benefit from the customized vision provided by the LAL technology.

Key Dates

Keywords

RxSight, Light Adjustable Lens, LAL, Light Delivery Device, LDD, cataract surgery, ophthalmic, financial results, revenue, gross margin, net loss